Business, energy, technology, markets and global industry news from Business News Today

Vertex Pharmaceuticals

Features & Analysis

Gene editing can nearly eliminate sickle cell crises. A daily pill may still reach far more patients

Gene therapy can transform sickle cell disease, but etavopivat shows why scalable oral treatments may ultimately reach a much larger patient population.

Read More
Features & Analysis

Risto-cel stopped severe sickle cell crises long enough for Beam to plan a BLA. Why did the stock still fall?

Risto-cel met its pivotal sickle cell endpoint, moving Beam toward a year-end BLA while manufacturing and transplant burden remain decisive.

Read More
Pharma & Biotech

AbCellera’s ABCL635 cut hot flashes by 83%. Can the biotech turn Phase 2 success into a viable drug?

AbCellera heads to UBS after positive ABCL635 Phase 2 results and a $200 million financing. Examine its clinical and commercial priorities.

Read More
Pharma & Biotech

Vertex Pharmaceuticals reports new Phase 3 RAINIER data for povetacicept in IgA nephropathy

Vertex's RAINIER trial shows 52% proteinuria reduction with povetacicept ahead of a November 30 FDA decision. Can it stand out in IgA nephropathy?

Read More
Pharma & Biotech

WuXi Biologics to support Vertex’s autoimmune TCE R&D with full CRDMO integration

Vertex licenses trispecific TCE from WuXi Biologics for autoimmune drug R&D. Explore platform risks, modality fit, and strategic expansion in this analysis.

Read More